Teladoc Q2 revenue down 2% to $642.4M; net loss $837.7M on $790M goodwill impairment; FY outlook withdrawn

Teladoc Health, Inc.

2024-Q2 EPS reported -$5.44 revenue$1,288,575,000

Q2 revenue $642.4M (-2% YoY); net loss $837.7M ($4.92/sh) includes $790M goodwill impairment for BetterHelp.
Adjusted EBITDA $89.5M (+24% YoY); Integrated Care +5% to $377.4M, BetterHelp -9% to $265.0M.
Company withdraws FY2024 consolidated and BetterHelp outlook and three-year outlook; provides Integrated Care guidance only.
New CEO Chuck Divita joined; comments on strengthening execution and streamlining organization.
Cash from operations $88.7M; free cash flow $60.9M; capex $27.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.